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New approaches from nanomedicine for
treating leishmaniasis
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Marcelo Caldero´n*a
Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 million
people in 98 countries around the world. There are already 12 million infected people worldwide and
two million new cases occur annually. Leishmaniasis has three main clinical presentations: cutaneous
(CL), mucosal (ML), and visceral (VL). It is considered an opportunistic, infectious disease and the
HIV-leishmaniasis correlation is well known. Antimonial compounds are used as first-line treatment
drugs, but their toxicity, which can be extremely high, leads to a number of undesirable side eﬀects and
resultant failure of the patients to adhere to treatment. There is also a reported increase in Leishmania
sp. resistance to these drugs. Nanotechnology has emerged as an attractive alternative because of its
improved bioavailability and lower toxicity, and other characteristics that help to relieve the burden of
this disease. In this review we will present some of the recent advances in the nanotechnological
research regarding the treatment of leishmaniasis. The preclinical results regarding the approaches for a
biomedical treatment of the disease have been encouraging, but further eﬀorts will still be necessary for
this therapy to have greater clinical applicability in humans.
1 Introduction
Leishmaniasis is a deadly infectious disease, caused by the
parasitic protozoan Leishmania, which is transmitted to mammals
by the bite of a phlebotomine sandfly vector.1,2 There are three
major forms of the infection: cutaneous (CL), mucosal (ML),
and visceral leishmaniasis (VL), also called kala-azar. Cutaneous
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manifestations can be subdivided into localized, diﬀuse,
leishmaniasis recidivans, and post-kala-azar dermal leishmaniasis.
Leishmaniasis is caused by 20 diﬀerent species that belong to
the genus Leishmania, including the L. donovani complex with
2 species (L. donovani, L. infantum also known as L. infantum in
America); L. mexicana complex with 3 main species (L. mexicana,
L. amazonensis, and L. venezuelensis); L. tropica; L. major; L. aethiopica;
and the subgenus Viannia (V) with 4 main species L. (V.) braziliensis,
L. (V.) guyanensis, L. (V.) panamensis, and L. (V.) peruviana. The
diﬀerent species are morphologically indistinguishable, but they
can be diﬀerentiated by isoenzyme analysis, molecular methods,
or monoclonal antibodies.1 Leishmaniasis threatens 350 million
people in 98 countries around the world.2 There are already
12 million infected people worldwide and two million new
cases occur annually. Leishmaniasis is also an important
opportunistic infection in HIV patients, which is potentially fatal,
even when treated appropriately. HIV infection can increase the
risk of VL’s development by 10–100 fold in endemic areas.3 The
Leishmania parasite exists in two life forms: an elongated, flagel-
lated promastigote in the midgut of the sandfly, and a small,
rounded, and non-motile form called amastigote inmacrophages
and other antigen presenting cells such as dendritic cells and
neutrophils.4,5 Once the sandfly bites the host in order to take a
meal, the parasites invade the local phagocytic host cells. Then
the promastigotes transform into amastigotes and multiply by
simple division inside the phagolysosomes of the resident macro-
phages. After a local dissemination, the distant macrophages get
infected. The parasite, host, and other factors affect whether
the infection becomes symptomatic and whether CL or VL
results. Sandflies become infected by ingesting infected cells
during blood meals1 (Fig. 1). Amastigotes living inside the
macrophage’s phagolysosomes represent the main target of
antileishmanial treatment, but they are not an easy target because
there are major structural barriers that antileishmanial drugs
have to overcome.
Eﬀective vaccines against this disease are still under develop-
ment and the available drugs can be quite toxic and costly, and
there may be some parasitic resistance.6 During the last seven
decades the chemotherapy for leishmaniasis has been depen-
dent on antimonial compounds. The old-fashioned pentavalent
antimonium-based (SbV+) drugs (Glucantime and Pentostam)
were developed and introduced as antileishmanials during
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the 1950s.7 These drugs have several flaws, including the need
of repeated parenteral administration, the occurrence of many
undesirable side eﬀects (including cardiotoxicity and pancreatitis),
as well as resistance from over usage.8 Drug combinations of
antimonials with allopurinol (a xanthine oxidase inhibitor) and
the antibiotic paromomycin very much improve the curative
outcome.9
In a second instance, the macrolide antifungal agent ampho-
tericin B (AmB) is a good alternative to the former compounds.
This fungicide, which is formulated as a deoxycholate salt or,
even better, is delivered by liposomes (AmBisome), has resulted
in a good therapy against visceral leishmaniasis, but it is extre-
mely expensive for developing and poor countries and requires
intravenous (i.v.) administration.10 A promising alternative to
(SbV+) is the alkylphosphocholine derivativemiltefosine (Impavido)
that was firstly synthesized as an antineoplasic drug. This
compound is the only oral drug prescribed against visceral
leishmaniasis.11,12 However, despite its proved eﬃcacy, milte-
fosine should not be administered to pregnant women due to
their teratogenic eﬀects. Finally, clinical studies performed
with the broad spectrum and low cost aminoglycoside anti-
biotic paromomycin (Humatin) have shown that the latter has
similar eﬃcacy with AmB but with fewer side eﬀects, and has
therefore been approved for the treatment of visceral leishmaniasis
in India.13 Many other compounds are considered second line drugs
for leishmaniasis including the aromatic diamidine pentamidine or
the antifungal azole fluconazole as well others with diﬀerent stages
of approval status. This suggests that we still need newer drugs and
delivery conditions. Fig. 2 discloses the chemical structures of some
of the typically used drugs.
Despite the eﬀorts of scientific community, compounds
included in preclinical studies do not move forward to develop-
ment. Current scenario of first and second-line drugs against
leishmaniasis obligates to strengthen interaction between
researchers developing new in vivo models and experts in nano-
materials. This is particularly important because leishmaniasis
is a complex of diseases with diﬀerent clinical manifestations as
a consequence of the anatomical distribution of parasites. These
diﬀerent locations might be a challenge that requires joint
eﬀorts of multidisciplinary teams, that should include chemists
Fig. 1 (1) The female sandfly transmits the protozoan by infecting itself with the Leishmania amastigotes contained in the blood of the human or
mammalian host. (2) The parasite continues its development inside the sandfly, where amastigotes transform into the promastigote form by binary
fission. (3) Promastigotes migrate to the pharynx and buccal cavity of the sandfly. (4) Sandfly bites its host and injects the promastigotes into the blood
stream. (5–7) Once in the host, the promastigotes are phagocytized by neutrophils and then by macrophages of the reticuloendothelial system where
they transform into the amastigote form. (8) Amastigote forms also multiply by binary fission, which leads to the cell’s rupture and liberation of these
forms into the circulation. Free amastigotes invade fresh cells. Some of them are taken up by the sandfly during its blood meal.
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that design new drug and delivery systems that are able to accu-
mulate at specific locations (spleen, liver, bone morrow, dermis)
after administration. However, the final market of these products
will be the poorest among the developing countries. Following
World Health Organization (WHO) recommendations, future
therapy in visceral leishmaniasis should be self-administrated by
patients, without the need of specialized professionals or infrastruc-
tures, meanwhile topical and photoactivatable therapies would be
eligible for cutaneous and mucocutaneous leishmaniasis.
The commonest and currently used animal models include
Balb/c mice and Syrian golden hamster (primary test) and dogs
(secondary test). Mice are used in acute infections that examine
the activity of the drug against the liver but not the spleen
infection. By its part, Syrian golden hamster infection provides
a simultaneous progression of disease in liver and spleen,
which develops into a chronic non-cure infection more similar
to human VL. Finally, during phase II and III in clinical trials the
most experimental animal in used is the dog. Drugs or vaccine
candidates are evaluated after a short period of time post-
treatment, using spleen and liver impression smears, which
involve the undesired euthanasia of animals. Although there is
not a consensual approach of in vivo drug evaluation, the most
used assays do not consider the assessment of similar parasitic
load in experimental animals before starting the treatment. In
addition, another disadvantage is that appraisal of the disease
for longer periods of time after the end of treatment, involves
performing repeated tissue biopsies by high qualify experts and
increasing the number of slaughtered animals.
These drawbacks are avoided by the use of in vivo real-time
imaging systems that allow the acquisition of images at
infection sites after inoculating the animals with genetically
modified parasites expressing reporters. These systems have
several advantages, namely, (a) eliminate the repeated biopsies,
the consuming time smear preparations and microscope analyses,
(b) allow treatment of animals with similar parasite loads,
(c) facilitate appraisal of infection for longer periods of times after
the end of treatment, (d) tackle individual evaluation through all
the period and (e) reduce the number of experimental animals. In
addition, these methods give access to periodic data of other
biomedical parameters from blood and urine that might inform
about toxicity at particular organs such as liver or kidney. Despite
the great need of novel diagnosis tools, almost no examples of
concepts based on nanomedicine have been reported related to
leishmaniasis. Combining new drugs, vaccines, or diagnostic
probes with appropriate delivery systems seems to be a promis-
ing approach to give response the WHO requirements against
clinical leishmaniasis in future.
The major challenge in the treatment of leishmaniasis is the
fact that the parasite infects the macrophage, therefore tradi-
tional antileishmanial drugs face diﬃculties to penetrate inside
the macrophages to kill the parasite.14 Recently, the combination
of antileishmanial drugs with nanocarriers has been emerging as
promising approach in the treatment of leishmania. These
nanocarriers have the ability to penetrate into macrophages,
release the drug inside the cell, leading to a local high concen-
tration of the therapeutic, and ultimately killing the protozoa. In
this sense, the main strategy in the treatment of leishmania is to
target the drugs directly to macrophages by using nanocarriers,
which have the ability to overcome biological barriers.15,16
Moreover, the use of nanocarriers would permit to reduce the
Fig. 2 Chemical structures of drugs typically used for the treatment of leishmaniasis.
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drug toxicity, enhance treatment eﬃcacy, improve selectivity,
modulate the drug pharmacokinetics, increase drug solubiliza-
tion, protect the drug from degradation, and promote a sustained
drug release directly in the target site.16 Another advantage is the
possibility to design the nanocarriers to carry more than one
drug, allowing the combination therapy that might have a syner-
gist eﬀect.17 Nanocarriers allow surface modification that should
be further investigated to increase parasite selectivity.
Nanoparticles like liposomes, polymers, and nanospheres
have proven to be very important for drug delivery as nano-
carriers. This technology may prove to be superior to current
treatment including reduced cost of drug, improved bioavail-
ability, and lower drug toxicity, which definitely enhances the
patient’s adherence to treatment. The use of nanotechnology
based formulations for the treatment of leishmaniasis has shown
promising results, however a higher attention of the scientific
community should be paid to such neglected diseases.18,19 This
review revises the recently reported research concerning nano-
technology against leishmaniasis in its three clinical forms, with
special emphasis on the utilization of liposomes, polymers, metal
nanoparticles, carbon-based materials, and nitric oxide (NO)
releasing nanoparticles.
2 Liposomes and nanoemulsions
Liposomes are small artificial vesicles of spherical shape that
can be created from cholesterol and natural non-toxic phos-
pholipids. Due to their size, biocompatibility, hydrophobic/
hydrophilic balance, stability, and flexibility to load various
molecules as cargo, liposomes are currently used as drug
delivery systems. Of all the nanomedicines implemented for
antileishmaniasis treatment, liposomes are perhaps the most
studied and therefore have the largest number of anticipated
clinical applications nowadays. The best example is AmBisomes,
a liposomal formulation of AmB which has proven to be success-
ful against leishmaniasis. In 1981, New et al. examined the eﬀects
of liposomal AmB (L-AmB) (Fig. 3)20 using the leishmania model
and reported that L-AmB had a lower toxicity than AmB itself and
that treatment with a higher dose of L-AmB could be feasible.
During the 80s several trials showed that L-AmB had a lower
toxicity than AmB in host animals and thus could be adminis-
tered at higher doses.21–23 A clinical trial performed by Lopez
Berestein et al. in 1985 in cancer patients with confirmed fungal
infection showed higher tolerance with L-AmB than with AmB.24
In 1987, Szoka et al. prepared small unilamellar vesicles
(SUV) containing sterol and explored the eﬀects of component
substances of liposome and size of the particle on the expression
of toxicity.25 They concluded that the sterol including L-AmB was
less toxic than without sterol. The authors also reported that
smaller liposomes are less toxic than larger liposomes, when
sterol was integrated. Based on these findings, NeXtar Inc.
succeeded in formulating the SUV type L-AmB.26 Studies pub-
lished between 1998 and 2005 focused on phase II dose optimi-
zation, mainly in the Mediterranean region of Europe and South
Asia, and confirmed earlier studies’ results showing that total
doses of 18–20 mg kg1 appeared effective, at least in non-
immuno compromised individuals.26 Also the use of conventional
liposomes with antileishmanial drugs proved to be asso-
ciated with an important reduction in their toxicity profile.27
AmBiosome’s market launch was in 1990 and then in August
1997 FDA approved its use for the treatment of patients with
VL, Aspergillosis, Candidiasis, and/or Cryptococcal infections
refractory or intolerant to AmB.20 However, its use continues to
be restricted in several areas due to its high cost.
In 2011 Roychoudhury et al. investigated the eﬃcacy of
sodium stibogluconate (SSG) in phosphatidylcholine stearylamine-
bearing liposomes (PC-SA-SSG), PC-cholesterol liposomes
(PC-Chol-SSG), and free AmB against SSG-resistant L. donovani
strains in 8-week infected BALB/c mice.28 Therapy with a single
dose of PC-SA-SSG was eﬀective in curing mice infected with
two diﬀerentially originated SSG-unresponsive parasite strains at
significantly higher levels than AmB, unlike free and PC-Chol-SSG.
Successful therapy correlated also with a complete suppression of
disease-promoting interleukin-10 (IL-10) and transforming growth
factor beta (TGF-b), upregulation of T helper cells (Th1) cytokines,
and expression of macrophage microbicidal. When administered
as PC-SA-SSG versus free SSG, due to the elevated accumulation of
Fig. 3 Schematic representation of liposomal formulation of amphotericin B.


































This journal is©The Royal Society of Chemistry 2016 Chem. Soc. Rev., 2016, 45, 152--168 | 157
SSG in intracellular parasites irrespective of SSG-resistance,
a cure happened as a result of increased drug retention and
improved therapy.
An interesting study by Perez et al. analyzed the in vitro
antileishmanial activity of liposomes with diﬀerent deformabi-
lity properties and loaded with the photosensitizer zinc phthalo-
cyanine (ZnPcAL).29 They compared two liposomal systems,
one of them built with soybean phosphatidylcholine, sodium
cholate, total polar archaeolipids (TPAs), and other one with an
ultradeformable character, lacking of TPAs. They found that the
photodynamic liposomes were innocuous against promasti-
gotes, however a low concentration (0.01 mM ZnPc and 7.6 mM
phospholipids) irradiated at a very low-energy density (0.2 J cm2)
eliminated L. braziliensis amastigotes from J774 macrophages
(Fig. 4), without reducing the viability of the host cells, HaCaT
keratinocytes, and bone marrow-derived dendritic cells. Interest-
ingly, they found that the only liposomes containing TPAs were
captured by macrophages, leading to 2.5-fold increased intra-
cellular delivery of ZnPc as compared to the ultradeformable
liposomes (UDL).
A layer-by-layer method to prepare nanocapsules (NCs) with
a nanoemulsion core loaded with doxorubicin (NCs-DOX),
which was further grafted with phosphatidylserine (PS) in order
to enhance the cellular uptake, was reported by Kansal et al. in
2012.30 The authors compared PS-NCs-DOX with non-PS-coated
NCs-DOX for their potential ability to target L. donovani para-
sites, which are known to cause VL. Cellular uptake by J774A.1
macrophages, intracellular localization, in vivo pharmacokinetics,
and organ distribution studies were performed. In vivo antileish-
manial activity of free DOX, NCs-DOX, and PS-NCs-DOX was
tested against VL in Leishmania donovani-infected hamsters. Flow
cytometric revealed 1.75-fold enhanced uptake of PS-NCs-DOX in
J774A.1 macrophage cell lines when compared with NCs-DOX.
In vivo organ distribution studies in hamsters demonstrated a
significantly higher extent of accumulation of PS-NCs-DOX com-
pared with NCs-DOX particularly in liver and spleen. There was
a significant improvement in the antileishmanial activity with
PS-NCs-DOX than with NCs-DOX. PS-NCs-DOX showed 85.23%
inhibition of the splenic parasitic burden, whereas NCs-DOX
and free DOX showed 72.88% and 42.85% parasite inhibition,
respectively, in Leishmania-infected hamsters. The parasite
inhibition with blank PS-NCs and NCs was 8.73% and 13.8%,
respectively (Fig. 5).30
3 Polymeric nanoparticles
To date, linear poly(ethylene glycol) (PEG), poly(lactide-co-glycolide)
(PLGA), polysaccharide based, and amino acid based polymers
have been successfully implicated, particularly to deliver bioactives
for the treatment of a series of diseases through the systemic
circulation. More recently, advanced polymeric architectures such
as dendritic polymers have been introduced and are now being
evaluated for their safety and ability to deliver therapeutic agents. A
growing volume of literature indicates that an array of structurally
diverse nanostructures of diﬀerent sizes, e.g., dendritic polymers,
prodrug conjugates, nanospheres, polyplexes, nanogels, polymeric
micelles, etc., are being developed for diagnostics or treatment
related purposes (Fig. 6).31,32
Polymeric nanocarriers possess advanced physicochemical
properties that improve bioavailability, biodegradability, enhance
cellular dynamics, and control targetability in drug delivery.33
In polymer-based drug delivery systems, a drug is either non-
covalently encapsulated in the interior of the polymer or covalently
conjugated to form a macromolecular prodrug. In the encapsula-
tion approach the release can be triggered by structural change
within the polymeric scaﬀold, i.e. backbone degradation, cleavage
of shell, charging of functional groups, etc., while in the macro-
molecular prodrug approach, the mechanism of release involves
the splitting of the linker between the polymer and the bioactive
agent.34 These characteristics are crucial to obtain an intracellular
delivery and sustained release of drugs at a therapeutically relevant
level.35 Therefore, the development that the field of polymeric
nanocarriers is currently experiencing could be of great use for the
treatment of leishmaniasis.
In 2013 Costa Lima et al. developed PLGA-based nano-
spheres (NS) containing AmB with suitable physicochemical
properties and anti-parasitic activity for VL therapy.18 BALB/c
mice infected with stationary phase promastigotes received
i.v. injection of a single-shot treatment of drug-free PLGA-NS,
AmBisomes, and a single or three consecutive daily doses of
AmB-PLGA-NS. Results showed significant in vitro and in vivo
AmB-PLGA-NS eﬃcacy and preferential accumulation in the
visceral organs. In addition, an immune-modulatory eﬀect was
Fig. 4 (A) Antiamastigote eﬃcacy of ZnPc (free or liposomal) in darkness or
after irradiation. (B, C) Optical microscopy of infected J774 cells incubated
with free ZnPc (B) or ZnPc on UDL (C). Reprinted with modifications from
ref. 29. Copyright 2014, Dove Press.
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observed in mice treated with AmB-PLGA-NS, correlating with
improved treatment eﬃcacy. The in vitro cytotoxic response of
the T-lymphocytes, which was accomplished using a LIVE/
DEAD cell mediated cytotoxicity kit, revealed that AmB-PLGA-
NS eﬃcacy against VL infection was strictly due to the action of
CD8+ but not CD4+ T lymphocytes. The authors could demon-
strate a crucial role for CD8+ cytotoxic T lymphocytes in the
eﬃcacy of AmB-PLGA-NS.
Andrographolide (AG) is a diterpenoid lactone extracted
from the leaves of the Indian medicinal plant Andrographis
paniculata that has been shown to be a potent antileishmanial
agent with low cytotoxicity. Roy et al. studied its eﬃcacy by loading
it into 50 : 50 poly(DL-lactide-co-glycolic acid) nanoparticles (AGnp)
stabilized by polyvinyl alcohol (PVA).36 Antileishmanial activity
in Albino mice macrophages was found to be significant for the
nanoparticle preparation with 4% PVA (IC50 34 mM) in about
one-fourth of the dosage of the pure compound AG (IC50 160 mM).
The authors then concluded this compound could provide an
eﬀective low-cost chemotherapy of leishmaniasis acting through
an alternative mechanism of leishmaniasis conventional therapy.
A step further was realized by Mondal et al. by studying AG’s
behavior against resistance.35 The authors designed AG nano-
particles with P-gp eﬄux inhibitor vitamin E D-a-tocopheryl
polyethyleneglycol succinate (TPGS). AGnps stabilized by vitamin E
TPGS were delivered into macrophage cells infested with sensitive
and drug resistant amastigotes of L. donovani parasites. Antileish-
manial activity was found to be significant for AGnp with TPGS in
about one-tenth of the dosage of the free AG and one-third of the
dosage of the AGnp without TPGS. Another important aspect was
cytotoxicity of AGnp, which was found to be significantly less with
or without TPGS than standard antileishmanial chemotherapeutics
like AmB, paromomycin, or sodium stibogluconate.
Fig. 5 (a) Plasma doxorubicin concentrations profiles of diﬀerent formulations administered intravenously in Wistar rats. (b) Eﬀect of NCs-DOX and
PS-NCs-DOX on hepatic and splenic uptake of doxorubicin. PS-NCs-DOX show significantly enhanced uptake in comparison with NCs-DOX (Po 0.05).
Reprinted with permission from ref. 30. Copyright 2012, Oxford Journals.
Fig. 6 Multifunctional polymeric nanocarriers according to diﬀerent chemical compositions and size.31
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A possible pathway to deliver compounds to the parasite
which is found within a parasitophorous vacuole (PV) in the
macrophages could be through polymer–drug conjugates.
These conjugates are taken into cells by endocytosis and then
trafficked through endosomes to lysosomes. The PV has a lot of
similarities to late endosomes/lysosomes and multiple vacuole
trafficking pathways can intersect with Leishmania PV. This
could mean that it is likely that the polymer–drug conjugates
can also be trafficked to this compartment.37 In 2012 Nicoletti
et al. decided to investigate polymer–drug conjugates based on
N-(2-hydroxypropyl)methacrylamide (HPMA). GlyPheLeuGly
(GFLG) was chosen as a linker from the polymer to the drug, in
this case AmB. This combination reports a high antileishmanial
in vitro and in vivo activity. When alendronate was added to this
backbone, however, there was not much improvement in the
antileishmanial activity than with HPMA–GFLG–AmB alone.37
Ko´cza´n et al. showed in 2002 that a branched polypeptide–
methotrexate conjugate with a polycationic carrier could increase
the effect of methotrexate (MTX) upon L. donovani infection in
mice, which led to an important antileishmanial activity.38 They
concluded that the covalent bond between carrier and this drug
is crucial for in vivo and in vitro activities. In 2003 Nan et al.
described an antileishmanial activity using HPMA–drug conju-
gates for the treatment of VL. Conjugates of HPMA copolymer
with NPC1161, an 8-aminoquinoline analog with antileishmanial
activity, containing N-acetylmannose-amine (ManN) in the
side chains, were synthesized and characterized in vitro and
in vivo (Fig. 7).39 ManN was conjugated to target the macrophages
of the reticuloendothelial system (RES). When compared to
nontargeted conjugates in mice, targeted conjugates were signifi-
cantly more effective against L. donovani amastigotes and also
showed a higher uptake.
Recently, Barros et al. prepared carbohydrate (mannan, MN)
functionalized PLGA nanosphere in the treatment of murine
VL.40 The authors demonstrated that MN-functionalized PLGA
nanospheres were successfully internalized by murine macro-
phages due to the high aﬃnity of the modified nanocarriers
towards mannose receptor on macrophages. In addition, by nano-
precipitation technique, amphotericin B (AmB) was incorporated
(encapsulation eﬃciencyB57%) into MN-functionalized PLGA
nanocarriers. In vivo experiments demonstrated that MN-
functionalized PLGA nanocarrier containing AmB reduced in
99.1  1.3% and 99.5  1.1% the parasitic load in the spleen
and liver, respectively; in comparison with as compared with the
vehicle control group. Moreover, administration of MN-PLGA
containing AmB in mice increased the production of important
cytokines involved in the infection of VL, such as INF-g, and
nitric oxide (NO), which plays a key role in the organism defense
against parasite infection. Therefore, AmB-containing MN-PLGA
nanocarriers demonstrated potential application in the treat-
ment of VL infection.
The behavior of dendrimers as potential antichagasic and
antileishmanial prodrugs was analyzed in 2011 by Giarolla et al.
by a molecular modeling study.41 The analyzed models contained
Fig. 7 Left panel: Structure of HPMA copolymer–NPC1161 conjugates. Right panels: In vitro microscopic images of mouse peritoneal macrophages
infected with L. donovani, prior to treatment (top) or after treatment (bottom) with polymer–drug conjugate. Reprinted with permission from ref. 39.
Copyright 2004, Elsevier.
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myo-inositol (dendrimer core), L-malic acid (spacer), and active
agents such as 3-hydroxyflavone, quercetin, and hydroxy-
methylnitrofurazone (NFOH). The authors modelled dendritic
molecules with four, five, and six branched modules. The
prodrug containing quercetin showed to be the most promising
candidate due to the ester linkage next to the myoinositol,
which should be hydrolyzed during dendrimer disassembly. In
2013 Daftarian et al. used a Pan-DR-binding epitope (PADRE)-
derivatized-dendrimer (PDD), complexed with L-AmB in a L.
major mouse model.42 They compared the therapeutic eﬃcacy
of low-dose PDD/L-AmB (6.25 mg per kg per day) with a full
dose of L-AmB (37.5 mg per kg per day). For this aim, meta-
cyclic promastigotes were injected intradermally on mice. They
concluded that PDD reduced the eﬀective dose and toxicity
of L-AmB and resulted in a stronger parasite specific T-cell
response (Fig. 8).
The main goal of vaccination is the induction of a protective
immune response against a specific pathogen. The physico-
chemical properties of polymer nanoparticles when used as
adjuvants in a vaccine could mean a more eﬀective immune
response against Leishmania. There have been several eﬀorts in
the last 5 years concerning immunization against leishmaniasis
through nanotechnology, mainly through the use of polymers.
In 2010 Tafaghodi et al. took PLGA nanospheres as an antigen
delivery system and Quillaja saponins (QS) as immunoadjuvant
to enhance the immune response against autoclaved L. major
(ALM).43 BALB/c mice were immunized three times in 3-week
intervals using the following formulations: ALM plus QS loaded
NS [(ALM +QS)PLGA], ALM encapsulated with PLGANS [(ALM)PLGA],
(ALM)PLGA plus QS, ALM plus QS, ALM alone, or phosphate
buﬀer saline (PBS). The footpad’s swelling size at the site of
injection was measured in order to analyze the intensity of
infection. Mice immunized with (ALM)PLGA showed a smaller
footpad swelling and the strongest protection. On the other
hand, (ALM + QS)PLGA group showed the least protection and
highest swelling, while the (ALM)PLGA + QS, ALM + QS and ALM
showed an intermediate protection with no significant diﬀerence.
With these results the authors concluded that PLGA NS could
increase the protective immune responses as a vaccine delivery
system and that QS adjuvant could have a reverse eﬀect on
protective immune responses.
4 Metallic nanoparticles and
carbon-based materials
Nanoparticles (NPs) are based on small well-defined aggregates
of the noble metals in the zero valent state. The size and the
shape of the nanoparticles can be controlled by the reducing
agent, the capping agent, and the reaction conditions used in
the preparation.44 Inherent properties of the noble metals,
enhanced due to the greater surface area of the nanoparticulate
form, could be of interest for the treatment of leishmaniasis. As
an example, the production of reactive oxygen species (ROS) by
silver NP is an antibacterial well-known eﬀect and Leishmania
parasites seem to be very sensitive to it as well. In 2011
Allahverdiyev et al. demonstrated an antileishmanial eﬀect using
Ag-NPs at concentrations ranging from 25 to 200 mg mL1.45 They
investigated the eﬀects of Ag-NPs on biological parameters of
L. tropica promastigotes such as morphology, metabolic activity,
proliferation, infectivity, and survival in host cells in vitro. When
exposed to Ag-NPs in the dark, L. tropica promastigotes lost
their shape and their internal organelles were no longer dis-
tinguishable. Similarly, when exposed to Ag-NPs in UV light, the
promastigotes membranes were disrupted and had an atypical
appearance. Furthermore, Ag-NPs showed a significant anti-
leishmanial eﬀect by inhibiting the proliferation and metabolic
activity of promastigotes by 1.5- to 3-fold, respectively in the
dark, and 2- to 6.5-fold, respectively, under UV light. Ag-NPs
also inhibited amastigotes survival in host cells, which was
more significant when UV light was present.
In 2012 Soflaei et al. analyzed the eﬀect of antimony sulfide
(Sb2S5) NPs upon L. infantum in vitro, which were synthesized
with a biological method from Serratia marcescens that had
Fig. 8 Therapy with PDD/LAmB at low dose was as eﬀective as that of LAmB at full dose. The skin lesions of the 2 groups were of comparable size
despite diﬀerent LAmB dosing. PDD conjugated with LAmB enhanced the eﬃcacy of LAmB treatment by at least 6-fold. Reprinted with permission from
ref. 42. Copyright 2013, Oxford University Press.
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been isolated from the Caspian Sea in northern Iran.46 This
parasite is known to be a VL etiological agent. The correlation
between cytotoxicity, concentration, and incubation time was
assessed on the promastigote and amastigote stages of this
parasite in the spleen macrophages of infected and uninfected
BALB/c mice. Sb2S5 NPs showed a positive and dose-dependent
eﬀectiveness on proliferation of promastigote form. The 50%
inhibitory concentration (IC50) of antimony sulfide NPs on
promastigotes was calculated to be 50 mg mL1. The authors
also concluded that this drug could induce apoptosis in pro-
mastigotes, which makes these particles useful for elimination
of the parasite (Fig. 9).
Metal oxide NPs, especially titanium dioxide (TiO2), silver
oxide (Ag2O), zinc oxide (ZnO), and magnesium oxide (MgO)
NPs, have been extensively explored by demonstrating signifi-
cant antibacterial activity. Jebali et al. studied the antileishma-
nial eﬀects of some NPs, including Ag-NPs, gold NPs (Au-NPs),
TiO2-NPs, ZnO-NPs, and MgO-NPs on L. major parasites under
UV, IR, and dark conditions (Fig. 10).47 They showed that
the highest antileishmanial activity was observed for Ag-NPs,
followed by Au-NPs, TiO2-NPs, ZnO-NPs, and MgO-NPs. Both
UV and IR light increased antileishmanial properties of all the
NPs. However, they observed that these NPs had cytotoxicity on
macrophages. The authors concluded that the use of NPs for
treatment of CL may have both positive and negative con-
sequences. Similarly, Mohebali et al. also demonstrated in their
work that Ag-NPs were eﬀective for control of secondary infec-
tion of localized CL.48
Prajapati et al. devised a novel way by using multi-walled
carbon nanotube to deliver an antileishmanial drug to over-
come drug-induced toxicity. AmB was linked to functionalized
carbon nanotubes (f-CNTs) to yield AmB-f-CNTs. The drug
carrier enhanced the drug’s eﬃcacy for inhibiting the growth
of L. donovani, a parasite that causes VL. AmB-f-CNT was
observed to be 14 folds more eﬀective than AmB for inhibiting
the growth of amastigotes. Furthermore, no toxicity to kidney
and liver in mice was observed. Interestingly, a higher suppres-
sion percentage of parasites in the spleen with AmB-f-CNT
(89.8%) was achieved compared to AmB (68.9%).49
5 Exogenous NO donors in the
treatment of cutaneous leishmaniasis
The endogenous free radical nitric oxide (NO) is an important
cellular signaling molecule that plays a key role in the defense
against pathogens.50,51 NO was elected the ‘Molecule of the
Year’ in 1992 due to its important physiological and patho-
physiological actions.52 In vivo, this ephemeral gas is synthe-
sized by one of three NO synthase (NOS) isoforms: endothelial
(eNOS), neuronal (nNOS), and inducible (iNOS). The isoforms
diﬀer in respect to regulation, amplitude, and duration of NO
production, as well as cellular and tissue distribution.53 Both
eNOs and nNOS are calcium-dependent isoforms and produce
low concentrations of NO (pico-nano molar range) for short
periods of time. At low concentrations, NO acts as intracellular
signaling molecule.54 The third isoform, iNOS, which is mainly
expressed in activated macrophages, is considered a compo-
nent of the innate immune system and produces high concen-
trations of NO (micro-mili molar range).51,55 NO produced by
mammalians iNOS has important cytostatic and cytotoxic eﬀects
against invading pathogens and parasites, including Leishmania
protozoa.56,57 Indeed, iNOS deficient mice are unable to control
the infection caused by Leishmania.58 In particular, activation of
infected macrophages by interferon (IFN)-g in CL increases the
expression of iNOS killing parasite via NO pathway.59 Although
the leishmanicidal mechanisms of NO are not fully elucidated,
it is assumed that NO may have apoptosis-like death eﬀectors,
while the toxicity of exogenous NO donors can be achieved
either by the release of free NO or by the S-nitrosation of
important parasite/host cell proteins.60–62 Either endogenous
or exogenous NO can inhibit intracellular and extracellular
Leishmania parasite.63,64
As Leishmania protozoa are able to compromise host macro-
phages decreasing iNOS activity, the administration of exogenous
NO donors represents an interesting strategy to combat CL.65
Hence, application of exogenous NO/NO donors is aimed to
supply the lack of endogenous NO production by infected macro-
phages. In this context, de Souza and collaborators incubated
L. major and L. amazonensis promastigotes with the NO donor
S-nitrosoglutathione (GSNO).64 Fig. 11 shows the concentration
dependent toxicity of GSNO on L. major (Fig. 11A) and
L. amazonensis (Fig. 11B) promastigotes, after 24 h of incubation.
In vitro 50% inhibitory concentrations (IC50) of 68.8  22.86 and
68.9  7.9 mmol L1 were found for L. major and L. amanzonesis,
respectively, upon GSNO treatment.64 These results demonstrate
the leishmanicidal activity of administration of high concentra-
tions of NO donor in protozoa cultures, highlighting their potent
therapeutic eﬀects to treat leishmaniasis.
Fig. 9 Viability of mouse macrophages contained amastigotes of Leishmania
infantum in 5 dilutions of antimony sulfide NPs during 24, 48, and 72 hours of
incubation. Reprinted with permission from ref. 46. Copyright 2012, Creative
Commons Attribution License.
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Ideally, exogenous NO donors should release sustained and
high concentrations of NO for longer periods of time to kill
Leishmania protozoa, leaving host tissues intact. In this context,
several NO-releasing vehicles have been developed to delivery
controlled amounts of NO in a safe manner. These approaches
range from direct application of gaseous NO66 to NO-releasing
nanomaterials.67 It should be noted that in CL parasites are
located in the dermis and in deep subcutaneous tissues,68
which makes it diﬃcult for the leishmanicidal agent to pene-
trate. The great advantage of using topical NO donors to combat
CL is based on the fact that NO intrinsically has the property to
rapidly diﬀuse though the dermis and lipid membranes, due to
its lipophilicity and small size.69
Topical application of a cream containing the NO donor
S-nitroso-N-acetylpenicillamine (SNAP) (final concentration
200 mmol L1) in human CL was first reported by Lopez-Jaramillo
et al. Administration of SNAP cream on patient lesions, caused
by L. braziliensis, was performed 4 times a day. After one month
treatment, the lesions were healed, since topical application
of S-nitrosothiols, such as SNAP, promotes and accelerates
Fig. 10 Proliferation of parasites after exposure with diﬀerent nanoparticles under (A) UV light, (B) IR light, and (C) at dark conditions. Reprinted with
permission from ref. 47. Copyright 2013, Elsevier.


































This journal is©The Royal Society of Chemistry 2016 Chem. Soc. Rev., 2016, 45, 152--168 | 163
wound contraction, in addition to their known cytotoxic eﬀects.70,71
In a similar approach, a NO generating topical formulation
comprised by acidified nitrite and ascorbic acid was applied on
BALB/c mice lesions caused by L. tropica.68 This NO-generating
formulation caused the cure of only 12% of the patients and
healing of 28% of the ulcer lesions.68 The importance of these
studies is that both works described the first approaches to
topically administrate NO donors/generators to combat CL with
no serious adverse eﬀects.
However, due to the uncontrolled NO release profile from
the formulations, the topical NO donors/generators need to be
frequently reapplied, which impairs the adherence to the treat-
ment. The lack of appropriate vehicles to stabilize NO donors
has been limited the clinical uses of NO. Thus, the diﬃculties of
promoting therapeutic amounts of NO, released in a sustained
and controlled manner, have motived the development of new
platforms to be used in the treatment of CL. Nanotechnological
approaches represent a very promising strategy to increase the
utility of NO in biomedical applications, such as in the treatment
of CL. The combination of nanoparticles and NO donors are
known to promote a controlled, sustained, and site direct NO
release, at required concentrations for desired therapeutic
applications.50,67
In this context, Lopez-Jaramillo et al. reported in 2010 the
controlled and sustained NO delivery from a topical nanofiber
NO releasing patch in the treatment of CL caused by L. (V)
panamensis. A multilayer transdermal patch, produced by an
electrospinning technique, produced a continuous and topical
flux of NO release (3.5 mmol NO per cm2 per day for 20 days).
In this nanomaterial, acidified nitrite and ascorbic acid were
encapsulated in the polymer nanofibers and led to a controlled
release of NO. The authors observed a 40% cure at 90 days
follow-up in patients treated with NO-releasing nanofibers.72
Similarly, poly(lactide-co-glycolide) NPs containing the NO donor
sodium nitroprusside (SNP) along with DOX were prepared as
potential leishmanicidal agent against VL. Encapsulation SNP in
the polymeric NP led to a sustained NO release for over 72 h,
however the synergetic leishmanicidal activity still has to be demon-
strated.73 Nanomaterials have the ability to guarantee a controlled
NO release at high concentrations, directly to the target site. Due to
the thermal and photochemical instability of NO donors, such as
S-nitrosothiols,74 their incorporation in nanomaterials has the
ability to greatly reduce the rates of NO release.67,71
Although the leishmanicidal actions of traditional NO
donors have been confirmed in in vitro and in vivo studies64,75
and despite that NO-releasing nanomaterials have been suc-
cessfully used in several biomedical applications,76 the combi-
nation of NO donors/generators with nanomaterials for combat
leishmaniasis has not been deeper explored. Nanomaterials
allied to NO is a convenient approach in the treatment of CL, as
already greatly explored in other biomedical applications, such
as in the promotion of wound healing, inhibition of platelet
aggregation or antibacterial eﬀects in cutaneous infections.71,77
In this scenario, several strategies have aimed to open new
perspectives for the treatment of CL with controllable and
sustainable release of therapeutic amounts of NO direct to
the target tissues, with minimum side eﬀects.
6 Nanoimmunization
Nanoparticles have not only been used as drug vehicles but also
as promising vaccine carriers. Vaccines are composed of appro-
priate antigens responsible for induction of a protective immune
response against a specific pathogen, boosted by adjuvants. Despite
many antigens are immunogenic to the host, the lack of universal
protection may result to the inability of the vaccine to elicit
desirable immune response.78 Nanoparticles can help to deliver
antigens to antigen-presenting cells (APCs) that play a crucial
role in activating the host immune system.79
The use of nanotechnology in delivering antigens and adju-
vants have diﬀerent aims: (i) to enhance their uptake by APCs,80
(ii) to generate Th1 type immune response,81 and (iii) to induce
a stronger immunological eﬀect due to a simultaneous delivery
to the same APC, compared to the free antigen and adjuvant.82
In the last years, the research in Leishmania vaccines is
trying to bridge the gap between humoral and cellular immune
responses. Dendritic cells (DCs) are a class of specialized APCs
that coordinate both innate and acquired immunity. They
sense the presence of microorganisms and recognize conserved
pathogen-associated molecular patterns. Mature DCs migrate
from the infection site to the closer draining lymph node for
antigen presentation to naı¨ve T-cells.83
The major challenge in Leishmania immunotherapy lies in
inducing a sustained life-long immunity against the parasite.
Eﬃcient leishmanicidal activity is obtained when naı¨ve
Fig. 11 Percentage of cell viability of L. major (A) or L. amazonensis (B) promastigotes upon incubation with diﬀerent concentrations of S-nitrosoglutathione
(NO donor) after 24 h. Reprinted with permission from ref. 64. Copyright 2006, Elsevier.
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CD8 + T-cells located at the lymph nodes are primed with the
CD4 + T-cell help. CD4 cells play a key role in the expansion of
CD8 cells, providing the properties of memory cells. However,
vaccines against Leishmania that reach clinical trials showed
low eﬃcacy due to scarce CD8 + T-cell response emerging from
cross-presentation.84
The physicochemical properties of polymer nanoparticles
when used as adjuvants in a vaccine could mean a more eﬀective
immune response against Leishmania. There have been several
eﬀorts in the last 5 years concerning immunization against
leishmaniasis through nanotechnology, mainly through the use
of polymers. In 2010 Tafaghodi et al. took PLGA nanospheres as
an antigen delivery system and Quillaja saponins (QS) as immuno-
adjuvant to enhance the immune response against autoclaved
L. major (ALM).43 BALB/c mice were immunized three times in
3-week intervals using the particulate antigen alone or in
combination with the immunoadjuvant. Immunized mice were
challenged with L. major at the footpad three weeks after the
last booster and the lesion size was measured in order to
analyze the intensity of infection. Mice immunized with parti-
culate ALM antigen showed the smaller footpad swelling and
the strongest protection in relation to the other formulations.
The authors concluded that nanoparticles could be used as a
vaccine delivery system.
Santos et al. tested two immunization strategies comparing
(a) unique priming using a PGLA nanoparticle loaded with
plasmid DNA encoding KMP-11 and (b) the above particulate
vaccine in combination with a 21-day delayed booster with the
same carrier loaded with recombinant protein KMP-11.85 Both
strategies showed detectable cellular immune responses with
pro-inflammatory and anti-inflammatory cytokines. After animal
challenge with L. braziliensis, although lesion development was
similar with both vaccination strategies, the parasite burden at
the lesion size was significantly reduced with the approach that
combines initial priming and a booster. Following the mice
inoculation with L. braziliensis, the group immunized with recom-
binant PLGA nanoparticles, showed upregulation of IFN-g and
TNF-a, which are proteins that orchestrate an immune defense
against pathogens, findings that could explain the greater parasite
killing at the site (Fig. 12).
In 2011 Doroud et al. evaluated the suitability of cationic solid
lipid nanoparticles (cSLN) as an adjuvant or delivery system for
cisteine proteinases (CPs) of L. major as target antigens in
C57BL/6 mice.86 They also determined the role of the C-terminal
extension (CTE) in CPs in the protective response. The results
indicated that encapsulation of CPs in cSLNs enhances the extent
of protection, showing a significant reduction in the parasite
burden of the draining lymph nodes. In addition, the CTE domain
proved not to have a crucial production of protective responses
against L. major infection.
Electroporation is an example of a physical vaccine DNA
delivery method that it is traditionally used for gene delivery.
It is believed to be a gold standard and it is defined as the
application of controlled electric fields to facilitate cell permea-
bilization, leading to the enhancement of gene uptake into cells
after injection of naked DNA. In 2013 Saljoughian et al. compared
the potential of either a physical method (electroporation) and
a chemical delivery system (cationic solid-lipid nanoparticles
cSLN) to deliver a DNA vaccine harbouring the L. donovani
A2 antigen along with L. infantum cisteine proteinases A and B
without its unusual C-terminal extension (A2-CPA-CPB-CTE).87
Deliver by either electroporation or cSLN formulation showed
protection of BALB/c mice against L. infantum through a
strong Th1 immune response. The cSLNs as a nanoscale
vehicle proved to be an interesting alternative as a delivery
system.
Based on the previous successful results, Shahbazi et al.
extended the research to a clinical trial using outbred dogs, since
they are primary reservoirs of the parasite.88 Results showed that
the administration of pcDNA-A2-CPA-CPB-CTE GFP vaccine as a
prime-boost by either electroporation or cSLN formulation protects
the dogs against L. infantum infection. But even more important
than that, was the fact that vaccinated dogs were associated with
significantly ( p o 0.05) higher levels of IgG2, IFN-g, and TNF-a
and with low levels of IgG1 and IL-10 as compared to the control
group, which correlates with a good Th1 immune response against
the parasite. Protection was also correlated with a low parasite
burden in bone marrow.
In the same way 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP) nanoliposomes were used as an antigen delivery system
and immunoadjuvant for soluble Leishmania antigens (SLA) by
Firouzmand et al. in 2013. They demonstrated that SLA incor-
porated within the nanoliposomes are appropriate delivery systems
to induce a Th1 type of immune response and protection against
L. major infection in BALB/c mice.89 Groups of mice immunized
with liposomal SLA showed very low number of parasites in the
Fig. 12 Cytokine expression at the ear dermis following a live challenge with parasites. (A) Mice immunized with plasmid DNA encoding L. infantum
chagasi KMP-11. (B) Mice immunized with PLGA NP. Reprinted with permission from ref. 85. Copyright 2012, Dove Press.
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footpad and spleen in comparison with the control group,
as well as the best Th1 response (high level of IFN-g and low
level of IL-4).
7 Advantages and limitations of
nanoparticulate systems in the
treatment of leishmaniasis
Traditional nanocarriers like liposomes and polymeric nano-
particles are readily internalized by macrophages in the liver
and spleen, therefore they are the preferred nanocarriers
employed in the treatment of macrophage parasitic diseases.15
Liposomes are definitely the most used nanocarrier in the
treatment of leishmaniasis. The positive aspects of liposomes
are the ability to load either hydrophilic or hydrophobic drugs,
the possibility to surface modifications, and the fate of lipo-
somes is the macrophage where the parasite exists. In particular,
surface modifications of liposomes are known to significantly
improve drug targeting, since macrophages express diﬀerent
receptors. Functionalization of liposomes with sugar can improve
macrophage targeting since macrophage contains receptors that
recognize sugar molecules. Similarly, positively charged lipo-
somes are readily internalized by macrophages due to their
interaction with negatively charged macrophage membrane.
However, liposomes display some limitations such as instabi-
lity that could lead to toxicity due to the leakage of the drug
from the nanocarrier into the blood stream.17 Nanoemulsions
are promising drug delivery systems due to their simple pre-
paration and scale-up, ability to solubilize hydrophobic drugs
and physicochemical stability.14
The second most popular nanocarrier used in the treatment
of leishmaniasis is polymeric nanoparticles, which can in part
overcome some limitations of liposomes.90 The advantages of
polymeric nanoparticles are the low toxicity, the possibility to
design biodegradable systems, the cost-eﬀectives, small size,
possibility to surface functionalization and co-administration
with others drugs. Among the polymers, biodegradable and bio-
compatible ones such as PLGA are preferred used. Polysaccharides
such as chitosan are also employed. By changing the polymer, the
physicochemical characteristic of the nanoparticles, such as zeta
potential, can be modulated.91 As liposomes, polymeric nano-
particles are internalized by macrophages, possess high surface
area that can be used for functionalization improving targeting
and biocompatibility, and stability in biological medium.16
Polymeric nanoparticles are more stable compared to lipo-
somes, thus extravasation of the drug before the nanocarrier
reach the target site (macrophage) can be avoided.
Metallic nanoparticles and carbon-based nanomaterials
have been emerging as versatile nanocarriers in the treatment
of leishmaniasis. From the revised literature, further studies
are necessary to explore the advantages of these nanocarriers in
this arena. In a similar manner, dendrimers are nanocarriers
with great potential to carry and delivery antileishmanial drugs
due to their ability to load with amounts of the drug on their
branched surface, improving the drug bioavailability.91
Although the recent advantages on the development of
eﬃcient antileishmanial releasing nanocarriers, there are some
challenges to be overcome. For example, the development of
eﬃcient oral nanoformulations for the treatment of leishmaniasis,
with low costs. In comparison with conventional pharmaceutical
drugs, the nanostructure formulations have higher costs. However,
it should be noted that traditional drugs often require sub-
stitutions for treatment due to lack of eﬃciency and undesired
side eﬀects, which can in turn result in further economic
investments.16
8 Conclusions
The crux of discovering a new chemical entity for any disease or
a disorder is to make sure it is safe, eﬃcacious, eﬀective, and
relatively inexpensive. Small molecules are known to be eﬀective,
but their ability to reach its target is limited by many intrinsic
physico-chemical traits. The eﬃcacy of these small molecules
could be further enhanced by various advanced techniques, e.g.,
by encapsulation or conjugation into/with nanocarriers like
liposomes, polymeric nanoparticles, dendrimers, carbon-based
materials, among others.31 Similarly, the systemic toxicity of the
small molecule drug can be reduced using this techniques and
by achieving enhanced bioavailability which results in increased
patient compliance. Conversely, the early diagnosis of the disease
is equally critical and a very challenging aspect of treatment. In
this direction, particularly for infectious diseases like leishma-
niasis, the U.S. Army Medical Material Development Activity
(USAMMDA) has conducted market research to survey available
or emerging technologies for a diagnostic device to detect CL.
Ideally the diagnosis of such diseases must be able to be used
in point-of-care settings and for the early treatment.
Treating leishmaniasis with first-line drugs such as AmB,
paromomycin, and miltefosine face many drawbacks since
such treatments are toxic and expensive. Furthermore many
of the Leishmania parasites are now resistant to these drugs.
Nano-based delivery systems deliberate many clinical advan-
tages, e.g., liposomal formulation of AmB is unquestionably
eﬀective, but could also be expensive. As we described in this
review, in recent years there have been several reported studies
as far as the treatment against leishmaniasis through nano-
technology is concerned. Some of them have shown encoura-
ging results that have allowed us to think that nanotechnology
might play a prudent role in the future, due to its many advan-
tages especially in comparison to the current antileishmanial
treatment. Liposomes, NCs, polymers, and NPs have been the
object of much study, because nanotechnology may not only be a
valuable tool in antileishmanial treatment but in prevention
(vaccines) as well. Interestingly, few nanotechnology based formu-
lations are being introduced in clinic for the treatment of leish-
maniasis. Recently, nano-liposomal AmB gel was approved in Iran
for the treatment of CL, fungal, and topical diseases.
As we already showed, the validity of in vitro and animal
model projects using nanotechnology as a treatment against
leishmaniasis is extremely important. However, none of the
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recently published studies mentioned further in vivo and clinical
tests, which could bring new challenges due to the large diﬀer-
ence between the two scenarios. Until today AmBisomes is the
only nanotechnology based antileishmanial drug, which has use
in the clinical practice, but, despite its proven eﬃcacy and low
toxicity among other features that make it an excellent alter-
native, its use remains restricted in some areas due to its high
cost. Further eﬀorts should be made in order to have more drugs
based on this promising technology in our future antileishmanial
drugs’ arsenal.
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